Drug Pricing Déjà Vu: The Biden-Harris Administration's Fiscal Year 2024 Budget Doubles Down on Inflation Reduction Act Reforms; CMMI and MedPAC Also Weigh In. | Akin Gump Strauss Hauer & Feld LLP
Are Accelerated Approval Drugs a New Target for Cost Reductions? As outlined in our prior analysis, the Inflation Reduction Act (IRA) included sweeping drug pricing reforms for the...
Source: jdsupra.com